Cantuzumab ravtansine
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | MUC1 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
868747-45-9  |
| ChemSpider | none |
 (what is this?) (verify) | |
Cantuzumab ravtansine (huC242-SPDB-DM4) is an antibody-drug conjugate designed for the treatment of cancers. The humanized monoclonal antibody cantuzumab (huC242) is linked to a cytotoxic agent, ravtansine (DM4).[1] It uses a more hindered disulphide linkage than Cantuzumab mertansine.[2]
See also
- Cantuzumab mertansine
- ImmunoGen Inc, developer of DM4 based drugs
References
- ↑ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
- ↑ Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to ...
This article is issued from Wikipedia - version of the 9/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.